The following is a summary of “Allergic fungal rhinosinusitis linked to other hyper-IgE syndromes through defective TH17 ...

▎药明康德内容团队编辑日前，阿斯利康（AstraZeneca）与安进（Amgen）合作开发的“first-in-class”单抗Tezspire（tezepelumab）针对伴有鼻息肉的慢性鼻窦炎（CRSwNP）患者进行的WAYPOINT临床3期试验 ...

Keywords: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Biologic therapies, Dupilumab, Omalizumab, Mepolizumab, Reslizumab, Benralizumab, Inflammatory pathways, Biologic treatment efficacy, ...

Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...

AstraZeneca (AZ) and Amgen have shared positive results from a late-stage study of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The phase 3 WAYPOINT trial ...

The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

Results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and congestion in CRSwNP.